Pamine® 2.5 mg/Pamine® Forte 5 mg Tablets
Pamine® 2.5 mg/Pamine® Forte 5 mg Tablets contain methscopolamine bromide, an anticholinergic agent.
Pamine (methscopolamine cation) is indicated for the following:
Adjunctive therapy for the treatment of peptic ulcer.
METHSCOPOLAMINE BROMIDE HAS NOT BEEN SHOWN TO BE EFFECTIVE IN CONTRIBUTING TO THE HEALING OF PEPTIC ULCER, DECREASING THE RATE OF RECURRENCE OR PREVENTING COMPLICATIONS.
Media Articles Related to Pamine (Methscopolamine)
UCSB study explores cocaine and the pleasure principle
Source: Health News from Medical News Today [2014.03.07]
On the other side of the cocaine high is the cocaine crash, and understanding how one follows the other can provide insight into the physiological effects of drug abuse. For decades, brain research has focused on the pleasurable effects of cocaine largely by studying the dopamine pathway. But this approach has left many questions unanswered.So the Behavioral Pharmacology Laboratory (BPL) at UC Santa Barbara decided to take a different approach by examining the motivational systems that induce an animal to seek cocaine in the first place.
Neurotensin conjugate provides pain relief in animal models
Source: Pain / Anesthetics News From Medical News Today [2014.02.19]
The small peptide neurotensin is a potent regulator of dopamine signaling and can provide dramatic pain relief; however, the blood brain barrier provides a substantial challenge toward clinical use of neurotensin for analgesia.
Source: MedicineNet Helicobacter Pylori Specialty [2012.05.16]
Title: Peptic Ulcer
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 5/16/2012 12:00:00 AM
Picture of Peptic Ulcer
Source: MedicineNet sucralfate Specialty [2010.04.15]
Title: Picture of Peptic Ulcer
Created: 4/15/2010 9:58:00 AM
Last Editorial Review: 4/15/2010 9:58:47 AM
Published Studies Related to Pamine (Methscopolamine)
Methscopolamine bromide blocks hypothalamic-stimulated release of growth hormone in ewes. [1997.05]
Twenty-five nonlactating ewes were used to test the hypothesis that methscopolamine bromide (MB) blocks secretion of growth hormone (GH) by affecting hypothalamic rather than pituitary mechanisms. Ewes were randomly assigned to receive a s.c...
The muscarine antagonist methscopolamine and the NMDA antagonist AP-5 injected unilaterally into the nucleus accumbens cause mice to rotate in opposite directions. 
Previously, we have reported that the NMDA antagonist AP-5, injected unilaterally into the nucleus accumbens of mice, induces ipsilateral rotation in monoaminergically intact mice, but contralateral rotation in monoamine-depleted animals. In this paper we report that the muscarine antagonist methscopolamine, injected unilaterally into the nucleus accumbens, induced predominantly contralateral rotation in monoaminergically intact mice...
Dorsal striatal mechanisms involved in the dopamine D2 receptor-mediated potentiation of apomorphine-induced jaw movements. [1994.01.24]
The role of dorsal striatal mechanisms in the regulation of apomorphine-induced jaw movements was studied. Jaw movements induced by apomorphine (0.2 mg/kg i.v.) were potentiated by quinpirole (10 micrograms/0.2 microliter) injected into the dorsal part of the striatum 10 min before apomorphine...
Seizure promotion by D1 agonists does not correlate with other dopaminergic properties. 
A range of D1 receptor agonists were tested for their ability to facilitate limbic motor seizures induced by a subthreshold dose of the chemoconvulsant pilocarpine (100 mg/kg IP) in mice. ED50 values (mumol/kg) were calculated from log dose-probit analyses, giving relative proconvulsant potencies of SKF 82958 > CY 208-243 > SKF 77434 = SKF 75670 = SKF 80723 > SKF 38393...